Fig. 1: Study population.
From: Gas6 in chronic liver disease—a novel blood-based biomarker for liver fibrosis
CCA cholangiocarcinoma, CLD chronic liver disease, CPS Child Pugh stage, CRCLM colorectal carcinoma liver metastases, CSPH clinically significant portal hypertension, HCC hepatocellular carcinoma, MELD model of end-stage liver disease.
